nicotinic acetylcholine receptor

A nicotinic acetylcholine receptor (nAChR) is a type of ion channel that opens directly when the neurotransmitter acetylcholine — or the alkaloid nicotine — binds to it. This makes it an ionotropic receptor: it converts a chemical signal into an electrical one in a single, rapid step, without the slower cascade of a G-protein.

nAChRs are found throughout the body. In the peripheral nervous system they sit at the neuromuscular junction, where they trigger muscle contraction. In the brain they are distributed across regions involved in attention, reward, and memory, making them a key target for both endogenous signalling and psychoactive substances.

They belong to one of two broad categories of acetylcholine receptor — the other being muscarinic receptors, which work through a slower, different mechanism. The nicotinic family is named for nicotine's ability to activate them selectively.

How it works · its role

When acetylcholine or another agonist binds, the nAChR channel opens and allows sodium and calcium ions to flow in while potassium flows out. This depolarises the neuron or muscle cell, generating a fast excitatory signal.

The receptor exists as several subtypes assembled from different protein subunits. The α4β2 subtype is the most prevalent in the brain and is centrally involved in the stimulant and reinforcement of nicotine. The α7 subtype, also widely expressed in the brain, is associated with cognitive function and attention. The α1-containing subtype dominates at the neuromuscular junction.

With repeated or sustained activation, nAChRs enter a desensitised state — the channel closes even though the agonist is still bound. Paradoxically, chronic exposure to nicotine leads to an increase in receptor number across much of the brain, a compensatory upregulation that is thought to underlie withdrawal when the drug is removed.

Relevance to substances & effects

Nicotine is the prototypical nAChR agonist and the substance most directly associated with this receptor class. Tobacco products and nicotine replacement therapies all act here, producing the characteristic alertness, reduced appetite, and mild reinforcement that drive use.

Varenicline, used in smoking cessation, works as a partial agonist at α4β2 receptors — active enough to reduce cravings but not strongly enough to reproduce the full effect of nicotine. Cytisine, a plant-derived alkaloid with a similar profile, is used for the same purpose in some countries.

Galantamine, used in Alzheimer's disease, has a dual mechanism: it inhibits the enzyme that breaks down acetylcholine and acts as a positive allosteric modulator of nAChRs, amplifying the receptor's response. Some general anaesthetics and dissociative agents block the channel pore of nAChRs among other targets, contributing to their sedating and analgesic profiles.

At the neuromuscular junction, curare-derived muscle relaxants used in surgery block nAChRs competitively, preventing acetylcholine from triggering contraction.

Tolerance & dependence

Tolerance to nicotine's subjective effects develops quickly — within days of regular use — largely because of receptor desensitisation. The receptor is present but unresponsive to the same dose, so users escalate or maintain intake to reach the same effect.

The receptor upregulation that follows chronic use creates a system calibrated around the presence of nicotine. When it is removed, the now-overabundant receptors receive less stimulation than they have adapted to expect, producing withdrawal: irritability, difficulty concentrating, increased appetite, and strong cravings.

This cycle — desensitisation driving tolerance during use, upregulation driving withdrawal on cessation — is the neurobiological core of tobacco dependence, one of the most persistent forms of drug dependence documented.